Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia  

作　　者：刘丽萍 LIU Liping(Dept Infect Dis,1st Affil Hosp,Nanchang Univ,Nanchang 330006)

机构地区：[1]Dept Infect Dis,1st Affil Hosp,Nanchang Univ,Nanchang 330006

出　　处：《China Medical Abstracts(Internal Medicine)》2023年第2期84-85,共2页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To observe the efficacy and factors influencing sequential or combined tenofovir alafenamide fumarate(TAF)after treatment with entecavir(ETV)in patients with chronic hepatitis B(CHB)with low-level viremia(LLV).Methods 126 CHB cases treated with ETV antiviral therapy in the Department of Infectious Diseases of the First Affiliated Hospital of Nanchang University from January 2020 to September 2022 were retrospectively collected.

关 键 词：FUMARATE TREATMENT AFTER 

分 类 号：R512.62[医药卫生—内科学]